Liquid biopsies that detect circulating tumour DNA (ctDNA) have the potential to
revolutionise the personalised management of colorectal cancer. For patients with early …

Breast cancer remains a leading cause of cancer-related death in women despite screening
and therapeutic advances. Early detection allows for resection of local disease; however …

Precision medicine describes a target-related approach to tailoring diagnosis and treatment
of the individual patient. While this personalized approach is revoluzionizing many areas of …

The current standard-of-care adjuvant treatment for patients with colorectal cancer (CRC)
comprises a fluoropyrimidine (5-fluorouracil or capecitabine) as a single agent or in …

Introduction Circulating tumor DNA (ctDNA) has been increasingly recognized as a
promising minimally-invasive biomarker that could identify patients with minimal residual …

Adjuvant chemotherapy following surgical intervention remains the primary treatment option
for patients with localized colorectal cancer (CRC). However, a significant proportion of …

Advancements in the clinical practice of non-small cell lung cancer (NSCLC) are shifting
treatment paradigms towards increasingly personalized approaches. Liquid biopsies using …

Precision radiotherapy refers to the ability to deliver radiation doses with sub-millimetre
accuracy. It does not however consider individual variation in tumour or normal tissue …

Importance The association of chronic inflammation with colorectal cancer recurrence and
death is not well understood, and data from large well-designed prospective cohorts are …

Simple Summary ctDNA is a small DNA fragment derived from tumor cells, which contains
tumor-related genomic information, such as mutation, methylation, microsatellite instability …